^
Association details:
| Biomarker: | BCL2 expression + MYC expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study
Published date:
12/30/2020
Excerpt:
...majority of the patients were treated with R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine) and prednisolone]...coexpression of MYC and BCL2 using a combination of MYC ≥60% with BCL2 ≥50% or >70% was associated with inferior PFS (HR 2.83 (1.12 to 7.20), p=0.035 and HR 2.84 (1.10 to 7.36), p=0.041, respectively) (figure 2C,D).
DOI:
10.1136/jclinpath-2020-207121
Source:
Title:
Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma
Published date:
11/01/2018
Excerpt:
...152 primary DLBCL patients treated with R-CHOP or R-CHOP-like regimen....Dual protein expression (DPE) of BCL2 and MYC was detected in 9.5% of the cases. DPE lymphomas were evenly distributed between the subtypes, and they had adverse prognostic significance independent of IPI and molecular subtype (Figure 1D).
DOI:
10.1182/blood-2018-99-117958
